Cingulate Inc. (CINGW)

US — Healthcare Sector
Peers: CING  EPRX.TO  HOOK  CELUW  NRSNW  DRMAW 

Automate Your Wheel Strategy on CINGW

With Tiblio's Option Bot, you can configure your own wheel strategy including CINGW - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol CINGW
  • Rev/Share 2957.6339
  • Book/Share 1.2557
  • PB 3.4244
  • Debt/Equity 1.1941
  • CurrentRatio 1.5184
  • ROIC -1.4757

 

  • MktCap 22637952.0
  • FreeCF/Share -3.9709
  • PFCF -1.2988
  • PE -1.0512
  • Debt/Assets 0.4887
  • DivYield 0
  • ROE -2.3216

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 5
  • P/B Score 4
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

About Cingulate Inc. (CINGW)

  • IPO Date
  • Website https://www.cingulate.com
  • Industry Biotechnology
  • CEO Shane J. Schaffer
  • Employees 13
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of central nervous system and neurobiological disorders. The company's lead product candidates are CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for the treatment of attention deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas with an additional location in Morristown, New Jersey.